Advances in sickle cell disease treatment: from drug discovery until the patient monitoring

Sickle cell disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. Nowadays the treatment is performed mainly with drugs such as hydroxyurea or othe...

Full description

Saved in:
Bibliographic Details
Published inCardiovascular & hematological agents in medicinal chemistry Vol. 9; no. 2; p. 113
Main Authors dos Santos, Jean Leandro, Lanaro, Carolina, Chin, Chung Man
Format Journal Article
LanguageEnglish
Published Netherlands 01.04.2011
Subjects
Anemia, Sickle Cell - drug therapy
Anemia, Sickle Cell - physiopathology
Animals
Antisickling Agents - pharmacology
Antisickling Agents - therapeutic use
Chelating Agents - pharmacology
Chelating Agents - therapeutic use
Drug Discovery - methods
Erythrocytes - drug effects
Erythrocytes - pathology
Hemoglobins - metabolism
Hemorheology - drug effects
Humans
Hydroxyurea - pharmacology
Hydroxyurea - therapeutic use
Nitric Oxide - metabolism
Plant Preparations - pharmacology
Plant Preparations - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Sickle cell disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. Nowadays the treatment is performed mainly with drugs such as hydroxyurea or other fetal hemoglobin inducers and chelating agents. This review summarizes current knowledge about the treatment and the advancements in drug design in order to discover more effective and safe drugs. Patient monitoring methods in SCD are also discussed.
ISSN:1875-6182
DOI:10.2174/187152511796196506